AI Reshaping Biopharmaceutical Decision-Making: A Paradigm Shift from Data to Insights

Introduction

Artificial intelligence is permeating every aspect of biopharma with an irreversible momentum. However, according to Henry Levy, President of Life Sciences and Healthcare at Clarivate, the real transformation is not about mere technology adoption, but a fundamental reshaping of decision-making models. In an interview with Fierce Biotech, Levy emphasized that AI-driven decision systems must be built on structured, high-quality data and combined with deep scientific expertise; otherwise, they may amplify errors instead of generating insights.

Industry Background

The biopharmaceutical industry has long faced challenges of low R&D efficiency and high clinical trial failure rates. Traditional decision-making relies on expert experience and limited data analysis, which is time-consuming and prone to bias. The intervention of AI provides the industry with unprecedented computational power: extracting patterns from massive amounts of literature, genomic data, and real-world evidence, greatly expanding the number of candidate drugs that can be evaluated. According to industry reports, AI can shorten the drug discovery phase by 30%-50%, but only if data quality and governance mechanisms are in place.

Key Developments

Levy of Clarivate pointed out that the application of AI in biopharma decision-making is shifting from "process optimization" to "strategic empowerment." This is reflected in three aspects:

1. Candidate Drug Screening: AI models can analyze millions of compound structures within hours to identify potential targets, whereas traditional methods take weeks. However, this capability also brings "noise risk"—the model may recommend candidates that are actually ineffective or highly toxic, requiring expert validation.

2. Clinical Trial Design: By analyzing historical trial data, patient electronic medical records, and real-world evidence, AI optimizes inclusion/exclusion criteria, predicts patient recruitment speed, and even simulates trial outcomes. For example, several CROs have adopted AI-assisted design for adaptive trials, reducing unnecessary patient exposure.

3. Investment Decision Support: In M&A, licensing, or early-stage project evaluations, AI platforms can integrate scientific data, market analysis, and regulatory history to provide probabilistic recommendations. However, Levy emphasized that final decisions must retain human judgment, as AI cannot understand business subtleties and regulatory politics.

Market Impact

AI is reshaping the value chain of the biopharmaceutical industry. Beneficiaries include:

• Large Pharma: Companies like Pfizer and Roche have deployed internal AI decision support systems, compressing early research cycles by weeks.
• AI Startups: Companies such as Recursion Pharmaceuticals and Exscientia have attracted significant investment through AI-driven discovery platforms. In 2025, the AI drug discovery sector raised over $4 billion in funding.
• CROs and Data Providers: Firms like IQVIA and Clarivate have launched integrated AI analytics services to help clients optimize their R&D portfolios.However, the industry is also facing divergence: companies with data infrastructure and AI talent will accelerate innovation, while those lacking these capabilities may fall behind.

Challenges and Risks

Levy warns that over-reliance on AI while neglecting data quality and mechanistic understanding could lead to "garbage in, garbage out." Major challenges include:

• Data silos and accessibility: Multi-source heterogeneous data is difficult to integrate and is restricted by privacy regulations.
• Interpretability: Deep learning models are often viewed as "black boxes," and regulators remain cautious about AI-driven decisions.
• Talent gap: There is a scarcity of professionals who understand both AI and biopharmaceuticals.
• Regulatory uncertainty: The U.S. FDA and European EMA are developing guidelines for the use of AI/ML in drug development, but a unified framework has not yet been established.

Future Outlook (3-5 Years)

Over the next 3-5 years, AI will evolve from a supporting tool to the core infrastructure for biopharmaceutical decision-making. Expected trends include:

a) Normalization of human-machine collaboration: Companies will establish a dual review mechanism of "AI experts + domain experts," with AI providing candidate solutions and humans making final judgments. b) Data governance first: Investing in structured, interoperable data platforms will become a priority for enterprises. c) Gradual regulatory clarity: The FDA is expected to issue formal guidelines for the use of AI in preclinical and clinical research by 2027, driving industry standardization. d) Continued capital influx: Venture capital will further focus on the vertical domain of AI + biopharmaceuticals, especially platforms with real-world data integration capabilities.

Conclusion

The transformation of biopharmaceutical decision-making by AI is essentially a power shift from experience-driven to data- and AI-driven collaboration. Companies must maintain scientific rigor while pursuing computational speed. As Levy puts it, the ultimate competitive advantage does not come from the algorithm itself, but from the organizational ability to seamlessly integrate AI insights with human expertise. This trend will profoundly impact R&D efficiency, capital allocation, and regulatory direction over the next five years.